Monitor for FDA approval milestones for SAB-142 and subsequent pricing amendments to the MSA, as they will determine the actual financial commitment. The exclusive manufacturing arrangement reduces supply-chain flexibility but provides certainty for scale-up.
Price Chart
Executive Summary
SAB Biotherapeutics entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial manufacturing of its product SAB-142. The 5-year agreement (post-FDA approval) includes a minimum aggregate spend of $36 million and grants Emergent exclusive manufacturing rights, with limited exceptions. No immediate financial impact as the contract is contingent on FDA approval and batch pricing is yet to be determined.
Key Financial Metrics
Key Facts
- MSA with Emergent BioSolutions Canada for manufacturing SAB-142 at Emergent's facility in Canada
- Term: 5 years from FDA approval of SAB-142
- Minimum aggregate spend of $36 million over the term (if FDA approval obtained)
- Emergent has exclusive manufacturing rights; SAB may use alternative source only under limited conditions
- Batch pricing and commercial terms to be set in future amendments
- Agreement effective April 28, 2026
Financial Impact
Minimum aggregate spend of $36 million over 5 years post-FDA approval, but no immediate revenue or cost impact disclosed.
Risk Factors
- FDA approval of SAB-142 is uncertain and may not occur
- Single-source manufacturing dependency on Emergent
- Batch pricing not yet fixed, could increase costs
- Termination penalties if minimum spend not met post-approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204125 |
| Document: sabs-20260428.htm | 0001193125-26-204125 |
| Document: 0001193125-26-204125-index-headers.html | 0001193125-26-204125 |
| Document: 0001193125-26-204125-index.html | 0001193125-26-204125 |
| Document: 0001193125-26-204125.txt | 0001193125-26-204125 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 4, 2026 25w ago | 8-K | $0.0358 $0.0140 | ▼ −60.89% | ▼ −63.63% | — |
Apr 22, 2026 26w ago | 8-K | $0.0358 $0.0162 | ▼ −54.75% | ▼ −59.53% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers